1. Virax will present at the World Immune Regulation Meeting on March 12. 2. The focus will be on T cell dysfunction in post-acute infection syndromes. 3. Virax showcases immune profiling products, engaging with researchers and potential customers. 4. The conference is expected to attract around 600 scientists and clinicians globally. 5. Virax’s technologies may target long COVID and other immune dysregulation issues.
Participation in a prominent conference may enhance Virax's visibility and credibility, akin to historical instances where biotech firms gained attention and saw stock price increases post-conference appearances.
The conference participation is significant for establishing industry relationships, which can drive future sales and stock price growth. Moreover, the emphasis on long COVID aligns with current healthcare trends, which are of importance to investors.
The upcoming presentation and engagement with researchers can lead to immediate interest and potential new partnerships, influencing stock performance in the near term.
Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that the company's management will present at the 19th World Immune Regulation Meeting (WIRM), which will take place March 12-15, 2025, in Davos, Switzerland.
Title: Evaluation of T cell dysfunction in post acute infection syndromes
Presenter: Dr. Nigel McCracken, Chief Operating Officer at Virax Biolabs
Date: Wednesday, March 12, 2025, at 20:00
Location: Foyer A1, The Congress Center, Davos, Switzerland
Additionally, the Company will be showcasing its portfolio of immune profiling products for research use at Booth 116, and management will be available for discussions with research organizations and potential customers.
WIRM 2025 is an esteemed conference where approximately 600 scientists and clinicians from around the globe gather to discuss the latest advancements in immunology. This four-day event combines top-tier scientific lectures, informal networking, and a poster exhibition, all set against the stunning backdrop of Davos.
Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform. T-Cell testing can be particularly effective in the diagnosis and therapeutics of post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.
For more information, please visit www.viraxbiolabs.com.
Russo Partners, LLC
Nic Johnson
12 West 27th Street
4th Floor
New York, NY 10001
M: 303-482-6405
info@viraxbiolabs.com
SOURCE Virax Biolabs